New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 6, 2014
05:19 EDTGWPHGW Pharmaceuticals receives Fast Track designation for Epidiolex
GW Pharmaceuticals announced that the FDA has granted Fast Track designation to GW's investigational cannabidiol product, Epidiolex, in the treatment of Dravet syndrome, a rare and catastrophic treatment-resistant form of childhood epilepsy. In addition to Dravet syndrome, GW plans to conduct a clinical development program for Epidiolex in the treatment of Lennox-Gastaut syndrome. Following receipt earlier in 2014 of orphan drug designation by the FDA in LGS, GW expects to hold a pre-IND meeting with the FDA for Epidiolex in the treatment of LGS in mid-2014, and expects to conduct two Phase 3 trials in LGS during 2015.
News For GWPH From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 14, 2014
18:20 EDTGWPHOn The Fly: After Hours Movers
Subscribe for More Information
17:26 EDTGWPHGW Pharmaceuticals CEO says market for Epidiolex may be expanded over time
Subscribe for More Information
14:55 EDTGWPHGW Pharma analyst day positive, reason for sell-off unclear, says Piper Jaffray
Subscribe for More Information
08:07 EDTGWPHGW Pharmaceuticals data should 'silence the doubters,' says Piper Jaffray
Subscribe for More Information
07:15 EDTGWPHGW Pharmaceuticals says Epidiolex physician reports show signals of efficacy
Subscribe for More Information
07:11 EDTGWPHGW Pharmaceuticals announces preliminary topline results of Phase 2a trial
Subscribe for More Information
06:38 EDTGWPHGW Pharmaceuticals to host research and development day
Subscribe for More Information
October 8, 2014
11:23 EDTGWPHGW Pharmaceuticals slides after U.K. body recommends against use of Sativex
Subscribe for More Information
10:24 EDTGWPHGW Pharmaceuticals weakness on NICE guidance 'irrational,' says Piper Jaffray
Subscribe for More Information
10:04 EDTGWPHNICE guidance does not recommend use of Sativex in MS care
In an update to its original 2003 guideline, the U.K.'s National Institute for Health and Care Excellence has set out how people with multiple sclerosis, or MS, can receive better care. In the update, NICE recommends that people with suspected MS should be referred to a consultant neurologist. MS should not be diagnosed on the basis of MRI findings alone and only a consultant neurologist should make the diagnosis of MS. The guidance does not recommend the use of the cannabinoid drug Sativex, manufactured by GW Pharmaceuticals (GWPH), or fampridine as they provide only a modest benefit at a significant cost to the NHS, NICE stated. Shares of GW Pharmaceuticals are down 7% in early trading following the publication of NICE's new guidelines.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use